Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.30
    OpenPayerBilling CodesMyeloproliferative Diseases and Disorders, Poorly Differentiated NeoplasmsDRG 827-myeloproliferative-disorders-or-poorly-differentiated-neoplasms-with-major-o-r-procedures-with-cc
    Ask Trek AI about this page

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with CC: Inpatient Reimbursement Overview

    DRG 827 addresses major operative admissions for myeloproliferative disorders or poorly differentiated neoplasms with a Complication or Comorbidity, reflecting high-intensity surgical and medical management. Proper diagnosis and procedure coding within this Diagnosis-Related Group matter for Medicare inpatient reimbursement because they affect payment weight and resource allocation.

    Customize your policy alerts

    Sign up for drg 827 policy alerts

    Get alerted when payer policies referencing 827 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 827 Overview

    DRG 827 covers hospital admissions for myeloproliferative disorders or poorly differentiated neoplasms that include major operating room procedures and have a Complication or Comorbidity. These cases typically involve significant surgical intervention in patients with complex hematologic or oncologic diagnoses, which increases resource use. The grouping influences Medicare payment by recognizing higher costs associated with operative care combined with the presence of complications or comorbidities. Accurate clinical documentation and coding determine assignment to this Diagnosis-Related Group and subsequent inpatient reimbursement.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Investigational perioperative management and operative technique studies for major O.R. procedures in patients with myeloproliferative disorders or poorly differentiated hematologic neoplasms: These trials focus on optimizing intraoperative blood product use, thrombosis and bleeding risk stratification, and anesthesia/surgical protocols for patients undergoing major surgeries such as splenectomy, central venous access with complex resections, or emergency laparotomies. The population is adult inpatients with myeloproliferative neoplasms (e.g., primary myelofibrosis, polycythemia vera, essential thrombocythemia) or poorly differentiated hematologic malignancies who require high-risk operations and have comorbid cytopenias or coagulopathies; outcomes measured include perioperative morbidity, transfusion requirements, and short-term mortality. Findings are directly relevant to surgical teams, hospitalists, and payers because optimized perioperative pathways can reduce intensive care utilization, shorten length of stay, and lower costly complications that drive DRG payments and resource use.
    • Comparative effectiveness and supportive care trials evaluating inpatient medical management strategies for complications of myeloproliferative disorders and poorly differentiated neoplasms: These studies compare approaches such as different thrombosis prophylaxis regimens, transfusion thresholds and growth-factor support, or timing/intensity of cytoreductive/chemotherapy interventions instituted during an acute admission. They enroll hospitalized patients presenting with disease-related complications (thrombosis, hemorrhage, symptomatic splenomegaly, cytopenia-related infections) and evaluate outcomes like readmission rates, complication rates, and need for subsequent major procedures. Results inform clinicians and payers about which inpatient medical strategies most effectively prevent downstream high-cost events and readmissions for this DRG population.
    • Post-discharge outcomes, care-transition, and health services research assessing readmission risk and long-term resource utilization after major operative admission: These observational and intervention studies follow patients discharged after major O.R. procedures with CC to identify predictors of 30- and 90-day readmission, functional recovery, and outpatient care needs, and test care-transition interventions (enhanced nursing follow-up, anticoagulation clinics, or rapid outpatient hematology pathways). The cohorts include survivors of index hospitalizations for myeloproliferative or poorly differentiated neoplasm–related operations who often have ongoing hematologic instability or need for systemic therapy; endpoints include readmission frequency, outpatient visit intensity, and post-discharge complications. This research matters to providers and payers because it targets reductions in costly readmissions and post-acute care utilization that impact bundled payments and total cost of care for DRG 827 admissions.

    Related Codes

    820-LYMPHOMA-AND-LEUKEMIA-WITH-MAJOR-O-R-PROCEDURES-WITH-MCC

    Lymphoma and Leukemia with Major O.R. Procedures with MCC: Inpatient Reimbursement Overview

    821-LYMPHOMA-AND-LEUKEMIA-WITH-MAJOR-O-R-PROCEDURES-WITH-CC

    Lymphoma and Leukemia with Major O.R. Procedures with CC: Inpatient Reimbursement Overview

    822-LYMPHOMA-AND-LEUKEMIA-WITH-MAJOR-O-R-PROCEDURES-WITHOUT-CC-MCC

    Lymphoma and Leukemia with Major O.R. Procedures without CC/MCC: Inpatient Reimbursement Overview

    823-LYMPHOMA-AND-NON-ACUTE-LEUKEMIA-WITH-OTHER-PROCEDURES-WITH-MCC

    Lymphoma and Non-Acute Leukemia with Other Procedures with MCC: Inpatient Reimbursement Overview

    824-LYMPHOMA-AND-NON-ACUTE-LEUKEMIA-WITH-OTHER-PROCEDURES-WITH-CC

    Lymphoma and Non-Acute Leukemia with Other Procedures with CC: Inpatient Reimbursement Overview

    825-LYMPHOMA-AND-NON-ACUTE-LEUKEMIA-WITH-OTHER-PROCEDURES-WITHOUT-CC-MCC

    Lymphoma and Non-Acute Leukemia with Other Procedures without CC/MCC: Inpatient Reimbursement Overview

    826-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-MAJOR-O-R-PROCEDURES-WITH-MCC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with MCC: Inpatient Reimbursement Overview

    828-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-MAJOR-O-R-PROCEDURES-WITHOUT-CC-MCC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms: Inpatient Reimbursement Overview

    829-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-OTHER-PROCEDURES-WITH-CC-MCC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms: Inpatient Reimbursement Overview

    830-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-OTHER-PROCEDURES-WITHOUT-CC-MCC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Other Procedures without CC/MCC: Inpatient Reimbursement Overview

    Showing 1–10 of 27

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.